Extracorporeal photopheresis in BK virus infection after kidney transplantation: current evidence and emerging clinical applications

Clicks: 9
ID: 337768
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #218 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract BK polyomavirus (BKPyV) infection is a major complication after kidney transplantation, with no approved antiviral therapy and management reliant on immunosuppression reduction, which increases rejection risk. This review outlines the biological rationale for extracorporeal photopheresis (ECP) in infectious settings and critically appraises the current evidence for its use in BKPyV replication and BKPyV-associated nephropathy (BKPyVAN). ECP is an immunomodulatory therapy that induces apoptosis of apheresis-isolated mononuclear cells via ex vivo exposure to a photoactivatable agent and UVA light; reinfusion promotes tolerogenic dendritic cells, regulatory T-cell expansion, and cytokine modulation. Its antiviral potential was first observed in cytomegalovirus, with ECP linked to reduced viral burden in heart, lung, and hematopoietic transplantation. Experience in BKPyV is more limited, restricted to small case series and reports, where ECP combined with immunosuppression reduction was associated with sustained reductions in viremia, reaching > 99% in individual series, without increased rejection. These uncontrolled, confounded designs cannot isolate an ECP-specific antiviral effect, and the proposed antiviral mechanism remains hypothetical. ECP may be a promising adjunctive strategy in selected high-risk patients with persistent BKPyV viremia or BKPyVAN, but prospective, controlled studies are needed to confirm efficacy and define optimal use.
Reference Key
openalex_W7224264333 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ángela González-Rojas, Marc Xipell, Víctor Joaquín Escudero-Saiz, Carolt Arana, Michael Nicoli, Jordi Rovira, Paola Andrea Charry, Marta Bodro, Pedro Ventura‐Aguiar, Miquel Lozano, Fritz Diekmann
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag251
URL
https://doi.org/10.1093/ckj/sfag251
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.